IOVANCE BIOTHERAPEUTICS, INC. annual report, FY2014

Business context and reporting period

This summary covers Lion Biotechnologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2014. The filing identifies the registrant as Lion Biotechnologies; the company is identified in the request metadata as Iovance Biotherapeutics. The company was a clinical-stage biotechnology business developing tumor-infiltrating lymphocyte (TIL) cell therapies, led by LN-144 for refractory metastatic melanoma. It had no approved products or product revenue.

Financial performance and position

Working capital was $43.31 million and the current ratio was reported as 28:1. The filing reports no long-term debt obligations; balance-sheet liabilities were current accounts payable and accrued items. Cash flow from financing was $35.46 million, including $32.24 million net proceeds from the December 2014 stock offering and $3.22 million from warrant exercises. Investing activities used $1.59 million, primarily for property and equipment. No meaningful operating margin is applicable because there was no revenue.

Material changes versus the prior period

• Operating expenses rose about 100% and R&D expense about 104%, reflecting expanded staffing, the Tampa research laboratory, manufacturing development, and other research activity.
• Net loss declined from $25.38 million to $12.03 million largely because 2013 included a $16.66 million non-cash Lion transaction charge and other unusual charges. Excluding the Lion transaction charge, management said the 2014 net loss increased about $3.50 million, primarily due to higher operating and R&D costs.
• Cash increased by $25.24 million during 2014, supported principally by equity financing. The December offering sold 6.0 million shares at $5.75 per share for approximately $32.2 million net proceeds.
• The company expanded its research operations and entered an exclusive Moffitt license in 2014. In January 2015, the NCI CRADA was expanded to additional cancer indications, with annual payments increasing from $1.0 million to $2.0 million.

Outlook, risks, contingencies and unusual items

• Development outlook: The FDA allowed the company-sponsored Phase 2 LN-144 trial to proceed in early 2015. Management anticipated enrollment beginning in mid-2015, a registration trial in 2016 if results supported it, and possible later BLA discussions. These are plans, not assurances; trial design and timing remained subject to data and FDA discussions.
• Funding outlook: Management expected approximately $20 million of 2015 spending and stated that available funds supported at least 24 months of planned operations. This estimate included the March 2015 public offering, which generated approximately $68.2 million net proceeds; that financing occurred after the reporting date.
• Clinical evidence and safety: An NCI Phase 2 study reported an objective response in about 54% of 101 refractory metastatic melanoma patients; 14 complete responders remained in remission as of November 2014. TIL treatment can involve severe or life-threatening toxicities, particularly from lymphodepletion and high-dose IL-2; fatal complications are possible. Historical treatment comparisons cited in the filing were not head-to-head randomized comparisons.
• Key business risks: The company had no commercial products, depended substantially on the NCI collaboration and third-party manufacturer Lonza, and faced clinical, regulatory, manufacturing, intellectual-property, reimbursement, competition, and future financing risks. The CRADA required $2.0 million annually after its January 2015 expansion and could be terminated on 60 days’ notice.
• Contractual commitments: The filing lists $27.83 million of contractual obligations, including $15.83 million of NIH obligations and $12.0 million of CRADA obligations. Many NIH payments depend on clinical, regulatory, or commercial milestones. The original NIH license also contemplated royalties on sales and milestone payments; later 2015 amendments added fees and obligations.
• Regulatory and legal matters: The company received an SEC subpoena in April 2014 in an investigation concerning stock promotions, cooperated, and reported no further SEC request as of the filing. A separate landlord-related suit was settled in November 2014 for $110,000, accrued at year-end.
• Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2014 because of insufficient closing-process review and too few financial-reporting personnel to ensure segregation of duties. The auditor issued an adverse opinion on internal controls, while issuing an unqualified opinion on the financial statements. Management planned remediation during 2015.
• Other items: Stock-based compensation was approximately $3.81 million in 2014. The company had an accumulated deficit of approximately $76.6 million and no recognized deferred tax asset because of a full valuation allowance. It reported no off-balance-sheet arrangements and no cash dividends.

Important facts for investors to verify

1. Progress, enrollment, safety, and efficacy results from the LN-144 Phase 2 study, and whether subsequent trial plans were agreed with the FDA.
2. Cash runway and spending against plan, including the use of the March 2015 offering proceeds and the costs of expanded CRADA work.
3. Manufacturing capacity, timelines, and comparability of the company’s TIL process with NCI clinical-trial processes.
4. Milestone, royalty, and other payment obligations under NIH and Moffitt licenses, and the status and enforceability of licensed patent rights.
5. Remediation and independent testing of the disclosed material weaknesses in internal control over financial reporting.
6. Any developments in the SEC subpoena matter, and potential dilution from outstanding warrants, options, preferred shares, or registered resale shares.